

10522227a

G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 49:CLASS 50:Atom 51:Atom 52:Atom 53:Atom 54:Atom
55:Atom 56:Atom 57:Atom 58:Atom 59:Atom 60:Atom 61:Atom 62:Atom 63:Atom
66:CLASS 67:CLASS 69:CLASS 70:CLASS 71:CLASS 72:CLASS 75:CLASS 76:Atom
77:Atom 78:Atom 79:Atom 81:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 18:21:58 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 841 TO ITERATE

100.0% PROCESSED 841 ITERATIONS

43 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 15081 TO 18559

PROJECTED ANSWERS: 467 TO 1253

L2 43 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 18:22:02 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 16157 TO ITERATE

100.0% PROCESSED 16157 ITERATIONS

898 ANSWERS

SEARCH TIME: 00.00.01

L3 898 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 18:22:06 ON 08 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Karen Cheng

10522227a

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Feb 2007 VOL 146 ISS 7
FILE LAST UPDATED: 7 Feb 2007 (20070207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 43 L3

=> fil stng

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.47 | 172.78 |

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 18:22:24 ON 08 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 2, 2007 (20070202/UP).

=> fil reg

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 1.02 | 173.80 |

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 18:32:38 ON 08 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0
DICTIONARY FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0


New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when

Karen Cheng

10522227a



conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10522227b.str

with


W

R⁵

X and

R³ defined

R³ - phenyl or thieryl



chain nodes :

49 66 67 69 75 81 97 98 99 101 102 103 104 105 106

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 50 51 52 53
54 55 56 57 58 59 60 61 62 63 70 71 72 76 77 78 79 83 84 85 86
87 88 89 90 91 92 93

chain bonds :

5-97 10-98 12-99 16-101 21-49 25-102 29-103 32-104 39-105 50-69 51-81
52-66 53-67 62-106 71-75

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-10 7-8 8-9 9-10 11-12 11-15 12-13 13-14
14-15 16-17 16-20 17-18 18-19 19-20 21-22 21-25 22-23 23-24 24-25 26-27
26-30 27-28 28-29 29-30 31-32 31-35 32-33 33-34 34-35 36-37 36-40 37-38
38-39 39-40 50-51 50-55 51-52 52-53 53-54 54-55 54-70 55-72 56-60 56-57
56-76 57-58 57-79 58-59 58-61 59-60 59-63 61-62 62-63 70-71 71-72 76-77
77-78 78-79 83-84 83-87 84-85 85-86 86-87 88-89 88-93 89-90 90-91 91-92
92-93

Karen Cheng

10522227a

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 5-97 6-7 6-10 7-8 8-9 9-10 10-98 11-12 11-15
12-13 12-99 13-14 14-15 16-17 16-20 16-101 17-18 18-19 19-20 21-22 21-25
21-49 22-23 23-24 24-25 25-102 26-27 26-30 27-28 28-29 29-30 29-103
31-32 31-35 32-33 32-104 33-34 34-35 36-37 36-40 37-38 38-39 39-40
39-105 50-69 51-81 52-66 53-67 54-70 55-72 56-60 56-57 56-76 57-58 57-79
58-59 58-61 59-60 59-63 61-62 62-63 62-106 70-71 71-72 71-75 76-77
77-78 78-79 83-84 83-87 84-85 85-86 86-87

normalized bonds :

50-51 50-55 51-52 52-53 53-54 54-55 88-89 88-93 89-90 90-91 91-92 92-93

isolated ring systems :

containing 50 :

G1:H,CH3

G2:S,N

G3:X,H,CH3,N

G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9]

G5:[*10],[*11]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 49:CLASS 50:Atom 51:Atom 52:Atom 53:Atom 54:Atom
55:Atom 56:Atom 57:Atom 58:Atom 59:Atom 60:Atom 61:Atom 62:Atom 63:Atom
66:CLASS 67:CLASS 69:CLASS 70:CLASS 71:CLASS 72:CLASS 75:CLASS 76:Atom
77:Atom 78:Atom 79:Atom 81:CLASS 83:Atom 84:Atom 85:Atom 86:Atom 87:Atom
88:Atom 89:Atom 90:Atom 91:Atom 92:Atom 93:Atom 97:CLASS 98:CLASS 99:CLASS
101:CLASS 102:CLASS 103:CLASS 104:CLASS 105:CLASS 106:CLASS

L5 STRUCTURE UPLOADED

=> d

L5 HAS NO ANSWERS

L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 18:21:08 ON 08 FEB 2007)

FILE 'REGISTRY' ENTERED AT 18:21:37 ON 08 FEB 2007

L1 STRUCTURE UPLOADED

L2 43 S L1

L3 898 S L1 FULL

Karen Cheng

10522227a

FILE 'CAPLUS' ENTERED AT 18:22:06 ON 08 FEB 2007
L4 43 S L3

FILE 'STNGUIDE' ENTERED AT 18:22:24 ON 08 FEB 2007

FILE 'REGISTRY' ENTERED AT 18:32:38 ON 08 FEB 2007
L5 STRUCTURE UPLOADED

=> s l5 full sub=l3

FULL SUBSET SEARCH INITIATED 18:33:12 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 898 TO ITERATE

100.0% PROCESSED 898 ITERATIONS 596 ANSWERS
SEARCH TIME: 00.00.01

L6 596 SEA SUB=L3 SSS FUL L5

=> fil caplus

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 41.10 | 214.90 |

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 18:33:19 ON 08 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Feb 2007 VOL 146 ISS 7
FILE LAST UPDATED: 7 Feb 2007 (20070207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l6


L7 7 L6

=> d ibib abs-hitstr tot

Karen Cheng


10522227a

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:349551 CAPLUS
 DOCUMENT NUMBER: 145:62826
 TITLE: Synthesis of imidazole based p38 MAP
 (mitogen-activated protein) kinase inhibitors under
 buffered conditions
 AUTHOR(S): Magnus, Nicholas A.; Diserod, William D.; Nevill, C.
 Richard, Jr.; Wepstec, James P.
 CORPORATE SOURCE: Chemical Product Research and Development Division,
 Eli Lilly and Company, Indianapolis, IN, 46285, USA
 SOURCE: Organic Process Research & Development (2006), 10(3),
 556-560
 CODEN: OPADFK; ISSN: 1083-6160
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 G1




AB Chemical developed to give access to multigram quantities of imidazole
 479754
 and several related analogs, e.g., I (R1 = H or F) for Eli Lilly's p38
 MAPK program targeting therapies to address inflammation was described.
 The mols. of interest had an iso-Pr sulfonyl group present on the
 2-aminobenzimidazole heterocycle that was found to be labile when heated
 in polar solvents and/or exposed to high or low pH. Due to this
 instability issue, the syntheses of the target mols. required optimizing
 Sonogashira reaction conditions, employing a buffered oxidative method to
 produce α -diones, developing buffered reaction conditions to
 generate imidazoles, and developing final recrystn. conditions.
 IT 660433-80-7P 890653-92-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of (benzimidazolyl)imidazoles for use as p38 MAP kinase
 inhibitors via Sonogashira coupling of (aryl)acetylenes with
 (iodo)benzimidazoles followed by oxidation with KMnO_4 and
 heterocyclization with (aryl)aldehydes and NH_4OAc)
 RN 660433-80-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-
 yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 660433-13-6 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[5-phenyl-2-[2-
 (trifluoromethyl)phenyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 660433-30-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[2-(2-chloro-6-fluorophenyl)-5-phenyl-1H-
 imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, dimethanesulfonate (9CI) (CA
 INDEX NAME)

CM 1


CRN 660433-29-4
 CMF C25 H21 Cl F N5 O2 S



CM 2

CRN 75-75-2
 CMF C H4 O3 S


L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 890653-92-6 CAPLUS
 CN Ethanol, compd. with 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-
 1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine (1:1) (9CI) (CA INDEX
 NAME)

CM 1

CRN 660433-80-7
 CMF C25 H21 F2 N5 O2 S



CM 2

CRN 64-17-5
 CMF C2 H6 O

$\text{H}_3\text{C}-\text{CH}_2-\text{OH}$

IT 660433-04-5P 660433-13-6P 660433-30-7P
 660433-34-1P 849064-43-3P 890653-93-7P
 890653-94-8P 890653-96-0P 890653-97-1P
 890653-98-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of (benzimidazolyl)imidazoles for use as p38 MAP kinase
 inhibitors via Sonogashira coupling of (aryl)acetylenes with
 (iodo)benzimidazoles followed by oxidation with KMnO_4 and
 heterocyclization with (aryl)aldehydes and NH_4OAc)
 RN 660433-04-5 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-(2-cyclohexyl-5-phenyl-1H-imidazol-4-yl)-1-[(1-


L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 660433-34-1 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[2-[2-fluoro-6-(trifluoromethyl)phenyl]-5-
 phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-,
 monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660433-33-0
 CMF C26 H21 F4 N5 O2 S



CM 2

CRN 75-75-2
 CMF C H4 O3 S



RN 849064-43-3 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[5-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-
 1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, monomethanesulfonate (9CI)
 (CA INDEX NAME)


CM 1

CRN 849064-42-2
 CMF C23 H25 F2 N5 O2 S

Karen Cheng

10522227a

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 75-75-2
CMF C H4 O3 S


RN 890653-93-7 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660433-80-7
CMF C25 H21 F2 N5 O2 S

CM 2

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 890653-97-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(1-methylethyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660433-95-4
CMF C22 H25 N5 O2 S

CM 2

CRN 75-75-2
CMF C H4 O3 S


Karen Cheng

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 75-75-2
CMF C H4 O3 S

RN 890653-94-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(4-chlorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660432-82-6
CMF C25 H22 Cl N5 O2 S

CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 890653-96-0 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2-chloro-6-fluorophenyl)-5-(2,4-difluorophenyl)-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 890653-95-9
CMF C25 H19 Cl F3 N5 O2 S

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 890653-98-2 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(1,1-dimethylethyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660433-06-7
CMF C23 H27 N5 O2 S

CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10522227a

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:962247 CAPLUS

DOCUMENT NUMBER: 143:266919

TITLE: Preparation of benzimidazole compounds as p38 kinase inhibitors for the treatment of cancer

INVENTOR(S): Bonjouklian, Rosanne; Dally, Robert Dean; De Dios, Alfonso; Del Prado Catalina; Miriam Filadelfa; Dominguez-Fernandez, Carmen; Jaramillo Aguado, Carlos; Lopez de Uralde-Garmendia, Beatriz; Montero Salgado, Carlos; Shepherd, Timothy Alan

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 85 pp.

CODEN: P10X02

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-----------------|-----------------|----------|
| WO 2005080380 | A1 | 20050901 | WO 2005-US24 | 20050121 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1720862 | A1 | 20061115 | EP 2005-711246 | 20050121 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| PRIORITY APPLN. INFO: | | | | |
| | | EP 2004-380022 | A | 20040203 |
| | | US 2004-563399P | P | 20040419 |
| | | WO 2005-US24 | W | 20050121 |


OTHER SOURCE(S): MARPAT 143:266919

GI




AB Benzimidazole compds. and their analogs I [wherein W = certain N-containing

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 863606-52-4 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[(1-methyl-4-phenyl-1H-imidazol-5-yl)-1-(2-methylpropyl)]- (9CI) (CA INDEX NAME)



RN 863606-88-6 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[3-(2,4-difluorophenyl)-1H-pyrazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 863606-90-0 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[1-(2-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

five-membered heteroaryl; Y = N, CH, CNH2 or CMe; R = alkyl, Ph, benzyl, etc., and pharmaceutically acceptable salts thereof], such as II, were prepd. as inhibitors of kinases, esp. p38 kinases. Exemplified compds. I showed inhibition for p38 kinase and suppression of TNF- α both in vitro and in vivo with IC50 values of ≤ 5 mM, < 100 nM and < 100 mg/kg, resp. Other biol. activities were also evaluated. Therefore, I and their pharmaceutical compns. are potentially useful for treating a disease or condition capable of being improved or prevented by inhibition of p38 kinase, such as cancer.

IT 863606-33-1P 863606-38-6P 863606-43-3P


863606-52-4P 863606-88-6P 863606-90-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(Inhibitor; preparation of benzimidazole compds. as p38 kinase inhibitors for the treatment of cancer)


RN 863606-33-1 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[2-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 863606-38-6 CAPLUS


CN 1H-Benzimidazol-2-amine, 1-(2-methylpropyl)-6-(5-phenyl-2H-1,2,3-triazol-4-yl)- (9CI) (CA INDEX NAME)



RN 863606-43-3 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[5-(2,4-difluorophenyl)-2-methyl-1H-imidazol-4-yl]-1-(1,2-dimethylpropyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 863605-50-9P 863605-51-0P 863605-52-1P

863605-53-2P 863605-54-3P 863605-55-4P

863605-56-5P 863605-57-6P 863605-58-7P

863605-59-8P 863605-60-1P 863605-61-2P

863605-62-3P 863605-63-4P 863605-64-5P

863605-65-6P 863605-66-7P 863605-67-8P

863605-68-9P 863605-70-3P 863605-72-5P

863605-75-8P 863605-78-1P 863605-81-6P

863605-83-8P 863605-85-0P 863605-87-2P

863605-88-3P 863605-90-7P 863605-92-9P

863605-94-1P 863605-95-2P 863605-96-3P

863605-98-5P 863606-00-2P 863606-02-4P

863606-04-6P 863606-06-8P 863606-07-9P

863606-08-0P 863606-09-1P 863606-10-4P

863606-11-5P 863606-12-6P 863606-13-7P

863606-15-9P 863606-17-1P 863606-19-3P

863606-21-7P 863606-23-9P 863606-25-1P

863606-27-3P 863606-28-4P 863606-29-5P

863606-30-8P 863606-32-0P 863606-34-2P

863606-35-3P 863606-36-4P 863606-37-5P

863606-40-0P 863606-41-1P 863606-44-4P

863606-46-6P 863606-48-8P 863606-50-2P

863606-51-3P 863606-53-5P 863606-56-8P

863606-57-9P 863606-60-4P 863606-61-5P

863606-63-7P 863606-65-9P 863606-67-1P

863606-69-3P 863606-71-7P 863606-73-9P

863606-75-1P 863606-77-3P 863606-79-5P

863606-81-9P 863606-83-1P 863606-85-3P

863606-87-5P 863606-89-7P 863606-91-1P

863606-92-2P 863606-95-5P 863606-98-8P

863607-00-5P 863607-02-7P 863607-04-9P

863607-06-1P 863607-08-3P 863607-10-7P

863607-12-9P 863607-13-0P 863607-15-2P

863607-17-4P 863607-19-6P 863607-21-0P

863607-22-1P 863607-24-3P 863607-26-5P

863607-28-7P 863607-29-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Inhibitor; preparation of benzimidazole compds. as p38 kinase inhibitors for the treatment of cancer)


RN 863605-50-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-cyclopentyl-6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)


Karen Cheng

10522227a


L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 863605-51-0 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 863605-52-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 863605-53-2 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-(2,5-diphenyl-1H-imidazol-4-yl)-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 863605-54-3 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-(cyclopropylmethyl)-6-[2-(2,6-difluorophenyl)-5-


L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 863605-58-7 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 863605-59-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-ethyl- (9CI) (CA INDEX NAME)




RN 863605-60-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-butyl-6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 863605-61-2 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-(2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863605-55-4 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 863605-56-5 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 863605-57-6 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-propyl- (9CI) (CA INDEX NAME)


L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 863605-62-3 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 863605-63-4 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-(cyclohexylmethyl)-6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 863605-64-5 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(1,1-dimethylethyl)-5-phenyl-1H-imidazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 863605-65-6 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(1-methylethyl)-5-phenyl-1H-imidazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Karen Cheng

1052227a


L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863607-28-7 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-methyl-1-(2-methylpropyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 863607-27-6
CMF C21 H21 F N4




CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 863607-29-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methylpropyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 863605-41-8P 863606-58-0P 863606-59-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzimidazole compds. as p38 kinase inhibitors for the treatment of cancer)

RN 863605-41-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[3-(2,4-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 863606-59-0 CAPLUS
CN Acetamide, N-[6-(1-methyl-4-phenyl-1H-imidazol-5-yl)-1-(2-methylpropyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 863606-59-1 CAPLUS
CN Acetamide, N-[6-(2-bromo-1-methyl-4-phenyl-1H-imidazol-5-yl)-1-(2-

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:159128 CAPLUS
DOCUMENT NUMBER: 142:348138
TITLE: Design of Potent and Selective 2-Aminobenzimidazole-Based p38α MAP Kinase Inhibitors with Excellent in Vivo Efficacy
AUTHOR(S): de Dios, Alfonso; Shih, Chuan; Lopez de Uralde, Beatriz; Sanchez, Concepcion; del Prado, Miriam; Cabrejas, Luisa M.; Martins, Fleite, Sehil; Blanco-Urgoiti, Jaime; Lorite, Maria Jose; Nevill, C. Richard, Jr.; Bonjouklian, Rosanne; York, Jeremy; Vieth, Michael; Wang, Yong; Magnus, Nicholas; Campbell, Robert M.; Anderson, Bryan D.; McCann, Denis J.; Giera, Deborah D.; Lee, Paul A.; Schultz, Richard M.; Li, Li C.; Johnson, Lea M.; Wolos, Jeffrey A.; Lilly S.A., Eli Lilly and Co., Alcobendas, Madrid, 28108, Spain
CORPORATE SOURCE: Journal of Medicinal Chemistry (2005), 48(7), 2270-2273
SOURCE: CODEN: JMCHAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:348138
AB We report the design and discovery of a 2-aminobenzimidazole-based series of potent and highly selective p38α inhibitors. The lead compound had low-nanomolar activity in both ATP competitive enzyme binding and inhibition of TNFα release in macrophages. Compound showed excellent pharmacokinetics properties and oral activity in the rat collagen induced arthritis model compared with other p38 reference compds. A SAR strategy to address CYP3A4 liability is also described.
IT 660432-75-7P 660432-77-9P 660433-83-0P 660433-87-4P 660433-94-3P 660434-06-0P 660435-18-7P 660435-22-3P 660435-29-0P 849064-41-1P 849064-43-3P 849064-45-5P 849064-46-6P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(design of potent and selective 2-aminobenzimidazole-based p38α MAP kinase inhibitors with excellent in vivo efficacy)
RN 660432-75-7 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-(5-phenyl-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)




RN 660432-77-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[5-(4-fluorophenyl)-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

Karen Cheng

10522227a

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Benzimidazol-2-amine, 6-[(2,4-difluorophenyl)-2-[(1,1-dimethylethyl)-1H-imidazol-4-yl]-1-[(1,1-dimethylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004143142 CAPLUS
 DOCUMENT NUMBER: 140:199326
 TITLE: Preparation of benzimidazoles and benzothiazoles as inhibitors of p-38 map kinase for treating metastasis or rheumatoid arthritis
 INVENTOR(S): Bonjouklian, Rosanne De Diego Gomez, Jose Eugenio; De Dios, Alfonso; Hamdouchi, Chafiq Hamdouchi; Li, Tieshao; Lopez De Uralde Garandea, Beatriz; Vieth, Michal; York, Jeremy Schulenburg; Dally, Robert Dean; Del Prado Catalina, Miriam Filadelfa; Jaramillo, Carlos; Martin Cabrejas, Luisa Maria; Montero Salgado, Carlos; Pleite, Sheila; Sanchez-Martinez, Concepcion; Shepherd, Timothy Alan; Wikel, James Howard
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|-------------------|-----------------|------------|
| WO 2004014900 | A1 | 20040219 | WO 2003-0519890 | 20030731 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG | | | |
| AU 2003256297 | A1 | 20040225 | AU 2003-256297 | 20030731 |
| EP 1554272 | A1 | 20050720 | EP 2003-784749 | 20030731 |
| EP 1554272 | B1 | 20061025 | | |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| AT 343572 | T | 20061115 | AT 2003-784749 | 20030731 |
| US 2005272791 | T | 20051208 | US 2005-522227 | 20050125 |
| PRIORITY APPLN. INFO.: | | | EP 2002-380178 | A 20020809 |
| | | | US 2002-421939P | P 20021029 |
| | | | WO 2003-0519890 | W 20030731 |
| OTHER SOURCE(S): | | MARPAT 140:199326 | | |
| GI | | | | |

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The present invention provides benzimidazoles and benzothiazoles (shown as I; W = imidazolyl, oxazolyl, pyrazolyl, oxopyrazolyl, thiazolyl, 1,2,3-triazolyl, or imidazo[2,1-b]benzothiazolyl; X = NR₄, S; R₅ = halo, H, NR₉R₁₀; addnl. details are given in the claims; e.g. II) as p-38 map kinase inhibitors. The disclosed compds. inhibit p-38 kinase and are useful in the treatment of metastasis or rheumatoid arthritis. All exemplified I inhibit the p38 kinase enzyme with an IC₅₀ of at least 5 μM. Four exemplified I were tested and found to suppress TNF-α in vitro with an IC₅₀ <100 nM; three of these suppressed TNF-α in vivo in mice with an IC₅₀ <100 mg/kg. Treatment of rats with II produced a dose-dependent inhibition of TNF-α synthesis, as measured in the synovial lavage fluid; the TMED₅₀ = 10 mg/kg. II caused 54%, 73%, and 95% inhibition of lung metastasis formation for the 3, 10 and 30 mg/kg dose levels, resp., in the B16F10 melanoma lung metastasis model. II showed excellent dose-dependent activities against p38 MAPK in tumors harvested 2.5 h after dosing, seen as a dose-dependent inhibition of MAPKAP-K2 phosphorylation. II exhibited time- and dose-dependent inhibition of MAPKAP-K2 phosphorylation in P815 tumors in vivo. At all doses of II in a rat collagen induced arthritis efficacy model, there was a significant reduction in ankle diameter with a maximum reduction of 46% at 30 mg/kg; prednisolone reduced the inflammation to pre-arthritis levels. Although the methods of preparation are not claimed, preparative procedures and/or characterization data are given for 119 intermediates and 253 examples of I. For example, 1-isopropylsulfonyl-2-amino-6-[2-(thien-2-yl)-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate was prepared in 97% yield by cyclizing thiophene-2-carboxaldehyde with 1-isopropylsulfonyl-2-amino-6-[(tert-butylidimethylsilyl)oxy]-a-(phenyl)acetylbenzimidazole in HOAc in the presence of Cu(OAc)₂ and NH₄OAc.


IT 660432-27-9P, 1-isopropylsulfonyl-2-amino-6-[1-benzyl-5-(2,4-difluorophenyl)-2-(methyl)imidazol-4-yl]benzimidazole 660432-69-9P, 1-isopropylsulfonyl-2-amino-6-[2-(thien-2-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660432-74-6P, 1-isopropylsulfonyl-2-amino-6-[2-(5-nitrothien-2-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660432-84-8P, 1-isopropylsulfonyl-2-amino-6-[2-(4-nitrophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660432-90-6P, 1-isopropylsulfonyl-2-amino-6-[2-[1-(tert-butoxycarbonyl)piperidin-4-yl]-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole 660432-91-7P, 1-isopropylsulfonyl-2-amino-6-[2-[1-(benzyloxycarbonyl)piperidin-4-yl]-5-

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (phenyl)imidazol-4-yl]benzimidazole 660433-80-7P, 1-isopropylsulfonyl-2-amino-6-[2-(2,6-difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-82-9P, 1-cyclopropylsulfonyl-2-amino-6-[2-(2,6-difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-93-2P, 1-isopropylsulfonyl-2-amino-6-[2-isopropyl-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole 660433-95-4P, 1-isopropylsulfonyl-2-amino-6-[2-isopropyl-5-(phenyl)imidazol-4-yl]benzimidazole 660434-35-5P 660434-36-6P 660434-54-8P, 1-isopropylsulfonyl-2-amino-6-[1-cyclohexyl-4-(phenyl)imidazol-5-yl]benzimidazole 660434-58-2P, 1-isopropylsulfonyl-2-amino-6-[1-(N-(tert-butoxycarbonyl)amino)cyclohexyl]-4-(phenyl)imidazol-5-yl]benzimidazole 660434-59-3P, 1-isopropylsulfonyl-2-amino-6-[1-(1,4-dioxaspiro[4.5]decan-8-yl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-73-1P, 1-isopropylsulfonyl-2-amino-6-[1-(4-methoxybenzyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-87-7P, 1-isopropylsulfonyl-2-amino-6-[1-cyclopropyl-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-03-0P, 1-isopropylsulfonyl-2-amino-6-[1-(p-nitrophenyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-18-7P, 1-isopropylsulfonyl-2-amino-6-[2-(piperidin-4-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660435-21-2P, 1-isopropylsulfonyl-2-amino-6-[1-(piperidin-4-yl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-36-9P, 1-isopropylsulfonyl-2-amino-6-[1-(4-oxocyclohexyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-39-2P, 1-isopropylsulfonyl-2-benzylamino-6-[4-(phenyl)imidazol-5-yl]benzimidazole 660435-45-0P, 1-isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-bromo-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-46-1P, 1-isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(4-chlorophenyl)-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-50-7P, 1-isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(trimethylsilyl)ethyl-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-53-0P, 1-isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(ethyl)-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-63-2P, 1-isopropylsulfonyl-2-amino-6-[1-cyclohexyl-2-bromo-4-phenylimidazol-5-yl]benzimidazole 660435-81-4P, 1-isopropylsulfonyl-2-amino-6-[2-methyl-5-(2,4-difluorophenyl)imidazol-4-yl]benzimidazole 660435-94-9P, 2-Amino-6-[1-cyclohexyl-4-(phenyl)imidazol-5-yl]benzothiazole 660435-95-0P, 2-Chloro-6-[1-cyclohexyl-4-(phenyl)imidazol-5-yl]benzothiazole
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; prep. of benzimidazoles and benzothiazoles as inhibitors of p-38 map kinase for treating metastasis or rheumatoid arthritis)
 RN 660432-27-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[(2,4-difluorophenyl)-2-methyl-1-(phenylethyl)-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)


Karen Cheng




RN 660432-69-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[5-phenyl-2-(2-thienyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 660432-74-6 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[2-(5-nitro-2-thienyl)-5-phenyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 660432-84-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[2-(4-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 660433-82-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-(cyclopentylsulfonyl)-6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 660433-93-2 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[5-(4-fluorophenyl)-2-(1-methylethyl)-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 660433-95-4 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(1-methylethyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 660432-90-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-5-(4-fluorophenyl)-1H-imidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 660432-91-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-5-phenyl-1H-imidazol-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 660433-80-7 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 660434-35-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-phenyl-1H-imidazol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 660434-36-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-(4-fluorophenyl)-1H-imidazol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)




1052227a


L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 660435-93-8 CAPLUS
CN 2-Benzothiazolamine, 6-(5-phenyl-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)




RN 660435-96-1 CAPLUS
CN 2-Benzothiazolamine, 6-(1-cyclohexyl-4-phenyl-1H-imidazol-5-yl)-N-ethyl- (9CI) (CA INDEX NAME)



RN 660435-97-2 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-(5-phenyl-1H-1,2,3-triazol-4-yl)- (9CI) (CA INDEX NAME)

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Double bond geometry as shown.




RN 660866-17-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(fluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 660866-16-0
CMF C25 H22 F N5 O2 S
CCI IDS



D1-F



CM 2


CRN 75-75-2
CMF C H4 O3 S




IT 660433-35-2, 1-Isopropylsulfonyl-2-amino-6-[2-(2-fluoro-4-nitrophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660434-12-8, 1-Isopropylsulfonyl-2-amino-6-[1-[(2-(trimethylsilyl)ethoxy)methyl]-2-formyl-5-(phenyl)imidazol-4-yl]benzimidazole 660435-62-1, 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-nitro-4-(2-

Karen Cheng

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 660435-98-3 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-(3-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 660435-99-4 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 660433-80-7
CMF C25 H21 F2 N5 O2 S




CM 2

CRN 110-16-7
CMF C4 H4 O4


L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

fluorophenyl)imidazol-5-yl]benzimidazole
RU: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of benzimidazoles and benzothiazoles as inhibitors of p-38 map kinase for treating metastasis or rheumatoid arthritis)


RN 660433-35-2 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-(2-fluoro-4-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 660434-12-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[2-formyl-5-phenyl-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 660435-62-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 6-[1-cyclopropyl-4-(2-fluorophenyl)-2-nitro-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




IT 660432-22-4P, 1-Isopropylsulfonyl-2-amino-6-[1-[(2-(trimethylsilyl)ethoxy)methyl]-2-formyl-4-(phenyl)imidazol-5-yl]benzimidazole 660432-25-7P, 1-Isopropylsulfonyl-2-amino-6-[1-benzyl-5-(3,5-difluorophenyl)-2-(2,4-difluorophenyl)imidazol-4-

1052227a

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ylbenzimidazole 660434-14-OP, 1-Isopropylsulfonyl-2-amino-6-[1-
 [[2-(trimethylsilyl)ethoxy]methyl]-2-[[piperidin-1-yl)methyl]-5-
 (phenyl)imidazol-4-yl]benzimidazole 660434-20-8P,
 1-Isopropylsulfonyl-2-amino-6-[2-[[N-[2-(piperidin-1-
 yl)ethyl]amino]methyl]-5-(phenyl)-1-[[2-(trimethylsilyl)ethoxy]methyl]imid-
 azol-4-yl]benzimidazole 660434-23-1P, 1-Isopropylsulfonyl-2-
 amino-6-[1-[[2-(trimethylsilyl)ethoxy]methyl]-2-[2-(ethoxycarbonyl)ethen-2-
 yl]-5-(phenyl)imidazol-4-yl]benzimidazole 660434-24-2P,
 1-Isopropylsulfonyl-2-amino-6-[1-[[2-(trimethylsilyl)ethoxy]methyl]-2-[1-
 (ethoxycarbonyl)ethyl]-5-(phenyl)imidazol-4-yl]benzimidazole
 660435-44-9P, 1-Isopropylsulfonyl-2-chloro-6-[1-(4-methoxybenzyl)-
 4-(phenyl)imidazol-5-yl]benzimidazole
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of benzimidazoles and benzothiazoles as inhibitors of p-38 map
 kinase for treating metastasis or rheumatoid arthritis)
 RN 660432-22-4 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[2-formyl-4-phenyl-1-[[2-
 (trimethylsilyl)ethoxy]methyl]-1H-imidazol-5-yl]-1-[[1-
 (methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 660432-25-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-[2-(2,4-difluorophenyl)-5-(3,5-difluorophenyl)-
 1-(phenylmethyl)-1H-imidazol-4-yl]-1-[[1-(methylsulfonyl)- (9CI) (CA
 INDEX NAME)




RN 660434-14-0 CAPLUS

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 660435-44-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, 2-chloro-6-[1-[[4-(methoxyphenyl)methyl]-4-phenyl-1H-
 imidazol-5-yl]-1-[[1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Benzimidazol-2-amine, 1-[[1-(methylsulfonyl)sulfonyl]-6-[5-phenyl-2-[[2-(1-
 piperidinyl)methyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-4-yl]-
 (9CI) (CA INDEX NAME)



RN 660434-20-8 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[[1-(methylsulfonyl)sulfonyl]-6-[5-phenyl-2-[[2-(1-
 piperidinyl)methyl]amino]methyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-
 imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 660434-23-1 CAPLUS
 CN 1H-Imidazole-2-acetic acid, 4-[2-amino-1-[[1-(methylsulfonyl)-1H-
 benzimidazol-6-yl]-α-methylene-5-phenyl-1-[[2-
 (trimethylsilyl)ethoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 660434-24-2 CAPLUS
 CN 1H-Imidazole-2-acetic acid, 4-[2-amino-1-[[1-(methylsulfonyl)-1H-
 benzimidazol-6-yl]-α-methyl-5-phenyl-1-[[2-
 (trimethylsilyl)ethoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:39684 CAPLUS
 DOCUMENT NUMBER: 138:401735
 TITLE: Preparation of phenyl substituted triazoles as
 selective inhibitors of ALK5 kinase
 INVENTOR(S): Gaster, Laramie Mary; Harling, John David; Heer, Jag
 Paul; Heightman, Thomas Daniel; Payne, Andrew Hele
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2003042211 | A1 | 20030522 | WO 2002-EP13482 | 20021114 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KS, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2467267 | A1 | 20030522 | CA 2002-2467267 | 20021114 |
| EP 1444232 | A1 | 20040811 | EP 2002-803039 | 20021114 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| BR 2002014160 | A | 20040928 | BR 2002-14160 | 20021114 |
| HU 200402227 | A2 | 20050228 | HU 2004-2227 | 20021114 |
| CN 1608065 | A | 20050420 | CN 2002-825914 | 20021114 |
| JP 2005518352 | T | 20050623 | JP 2003-544047 | 20021114 |
| US 2005014938 | A1 | 20050120 | US 2004-495414 | 20040513 |
| NO 2004002244 | A | 20040713 | NO 2004-2244 | 20040528 |
| PRIORITY APPLN. INFO.: | | | GB 2001-27430 | A 20011115 |
| | | | WO 2002-EP13482 | W 20021114 |

OTHER SOURCE(S): MARPAT 138:401735
 GI



AB The title compds. [I: R1 = (un)substituted naphthyl, Ph, or Ph or pyridyl
 fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein
 said

Karen Cheng

10522227a


103

Date to beat- 10/28/02

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S; R2 and R3 = H, alkyl, alkoxy, etc.; two of X1, X2 and X3 = N and the other = NR4 (wherein R4 = H, alkyl, cycloalkyl, etc.) which are inhibitors of the transforming growth factor, TGF- β signaling pathway, in particular, the phosphorylation of smad2 or smad3 by the type I or activin-like kinase-5 (ALK-5) receptor, were prepd. Thus, heating a soln. of 6-(3-chlorophenylethynyl)-[1,2,4]triazolo[1,5-a]pyridine (prepn. given) and azidotrimethylsilane in DMF at 130°C for 19 h afforded 35% II. The compds. I generally show ALK5 receptor modulator activity having IC50 values in the range of 0.0001 to 10 μ M.

IT 528892-29-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of Ph substituted triazoles as selective inhibitors of ALK5 kinase)

RN 528892-29-7 CAPLUS
CN 1H-Benzimidazole, 6-[5-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

need find GB application?

R5 = H
X = N(R4)
R4 = H
R3 = phenyl subst. w/ Cl.

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:849613 CAPLUS
DOCUMENT NUMBER: 137:353066
TITLE: Preparation of nitrogenous fused-ring compound having pyrazolyl group as substituents as inhibitors of activation of signal transduction and activation of transcription (STAT6) protein
INVENTOR(S): Yoshida, Ichiro; Yoneda, Naoki; Ohashi, Yoshiaki; Suzuki, Shuichi; Miyamoto, Mitsuki; Miyazaki, Futoshi; Seshimo, Hidenori; Kanata, Junichi; Takase, Yasutaka; Shirato, Manabu; Shimokubo, Daiya; Sakuma, Yoshinori; Yokohama, Hiromitsu
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1006 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------|--|----------|-----------------|------------|
| WO 2002088107 | A1 | 20021107 | WO 2002-JP4156 | 20020425 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| EP 1382603 | A1 | 20040121 | EP 2002-722791 | 20020425 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| US 7074801 | B1 | 20060711 | US 2003-475585 | 20031023 |
| PRIORITY APPL. INFO.: | | | JP 2001-129959 | A 20010426 |
| OTHER SOURCE(S): | | | WO 2002-JP4156 | W 20020425 |
| GI | | | | |




AB The 4-(N-containing fused aromatic heterocyclyl)pyrazoles (I) or salts thereof,

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
or hydrates of either [X = a nitrogenous fused arom. heterocyclic group, e.g., imidazo[1,2-a]pyridine, having (R4)n as a substituent; wherein n = an integer of 0-3; R4 = H, halo, cyano, OH, NH2, C1-6 alkyl, halo-C1-6 alkyl, C2-6 alkenyl, C1-6 alkylsulfonyl, C1-6 alkylsulfonylamino, C1-6 alkylsulfinyl, N-mono, or N,N-di(C1-6 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfinyl, CONH2, etc.; Y = C3-8 cycloalkyl, C4-8 cycloalkenyl, 5- to 14-membered nonarom. or arom. heterocyclyl, C6-14 arom. hydrocarbonyl, benzene- or 5- or 6-membered arom. heterocycle-fused 5- to 7-membered nonarom. ring group; Z = H, NH2, halo, HO, NO2, cyano, N3, CHO, HONEH, SO2NH2, guanidino, oxo, C2-6 alkenyl, C1-6 alkoxy, etc.; R1 = H, halo, HO, NO2, cyano, halo-C1-6 alkyl, hydroxy- or cyano-C1-6 alkyl, C2-6 alkenyl, etc.; R2 = H, pyrazolyl; R3 = H, halo, cyano, NH2, C1-4 alkyl, halo-C1-4 alkyl] are prepd. These compds. are inhibitors of STAT6 protein activation and IL-4 and/or IL-13 signal transduction and are useful for prevention and/or treatment of diseases on which the inhibition of STAT6 activation and/or IL-4 and/or IL-13 signal transduction is effective. The diseases include allergy, allergic rhinitis, bronchial asthma, atopic dermatitis, pollinosis, digestive tract allergy, urticaria, hypersensitivity pneumonia, lung aspergillosis, eosinophil leukemia, parasite infection, eosinophilia, eosinophil pneumonia, eosinophil gastroenteritis, autoimmune disease, systemic lupus erythematosus, virus infection, bacteria infection, obesity, overeating (hyperphagia), malignant tumor, and acquired immunodeficiency syndrome (AIDS). Thus, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile was coupled with 6-[3-(4-fluorophenyl)-1-trityl-1H-pyrazolyl]-3-iodobenzonitrile with 2-allylpyridine in the presence of tetrakis(triphenylphosphine)palladium and K3PO4 in DMF at 75° for 3 h followed by treating a soln. of the coupling product in THF and MeOH with 5 N aq. HCl to give 4-[6-[3-(4-fluorophenyl)-1H-4-pyrazolyl]imidazo[1,2-a]pyridin-3-yl]benzonitrile dihydrochloride (II). II showed IC50 of <10 nM for inhibiting the IL-4-induced induction of alkali phosphatase in human embryonic kidney cell transfected with STAT gene and STAT reporter gene.


IT 474695-63-1P 474695-71-1P 474695-74-4P
474695-75-5P 474695-76-6P 474695-77-7P
474695-78-8P 474695-79-9P 474695-80-2P
474695-81-3P 474701-68-3P 474701-69-4P
474701-70-7P 474701-71-8P 474701-72-9P
474706-30-4P 474706-31-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of (N-containing heterocyclyl)pyrazole as inhibitors of activation of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as preventives and/or remedies of diseases)

RN 474695-63-1 CAPLUS
CN 1H-Benzimidazole, 1-(4-fluorophenyl)-6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 474695-71-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-(4-fluorophenyl)-6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 474695-74-4 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Karen Cheng

1052227a

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 474695-75-5 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[6-[3-(4-(methylsulfonyl)phenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, trihydrochloride (9CI) (CA INDEX NAME)




RN 474695-76-6 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[6-[3-(4-(methylsulfonyl)phenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 474695-77-7 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[6-[3-(4-cyanophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 474695-78-8 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[6-[3-(4-cyanophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl-, trihydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 474695-79-9 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 474695-80-2 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[6-[3-(3-cyanophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●3 HCl

RN 474695-81-3 CAPLUS
 CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-[5-(methylsulfonyl)-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl


RN 474701-68-3 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl-, trihydrochloride (9CI) (CA INDEX NAME)

1052227a

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 474701-69-4 CAPLUS
CN Morpholine, 4-[[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-3-pyridinyl]carbonyl-, dihydrochloride (9CI) (CA INDEX NAME)




RN 474701-70-7 CAPLUS
CN Pyrrolidine, 4-[[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-3-pyridinyl]carbonyl-3-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●3 HCl


RN 474706-30-4 CAPLUS
CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2,4-difluorophenyl)-1H-pyrazol-4-yl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 474706-31-5 CAPLUS
CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2-fluorophenyl)-1H-pyrazol-4-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●2 HCl


RN 474701-71-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 474701-72-9 CAPLUS
CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2,6-difluorophenyl)-1H-pyrazol-4-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●3 HCl

IT 474701-59-2P 474701-60-5P 474701-61-6P
474701-62-7P 474701-63-8P 474706-26-8P
474706-27-9P 474707-04-5P 474707-06-7P
474709-99-4P 474710-00-4P 474711-65-4P
474711-70-1P 474711-73-4P 474711-75-6P
474711-76-7P 474711-77-8P 474711-78-9P
474711-79-0P 474711-82-5P 474711-84-7P
474712-65-7P 474712-66-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (N-containing heterocyclyl)pyrazole as inhibitors of activation of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as preventives and/or remedies of diseases)
RN 474701-59-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)



Karen Cheng


10522227a

possible
102 \Rightarrow ask if CPh₃

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 474701-60-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 474701-61-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 474701-62-7 CAPLUS

CN Morpholine, 4-[[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 474706-27-9 CAPLUS

CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 474707-04-5 CAPLUS

CN 1H-Benzimidazole, 5-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 474707-06-7 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)


Karen Cheng

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 474701-63-8 CAPLUS


CN Pyrrolidine, 1-[[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-3-pyridinyl]carbonyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 474706-26-8 CAPLUS


CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2,4-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 474709-99-4 CAPLUS

CN 1H-Benzimidazole, 5-[3-(2,6-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 474710-00-4 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [6-[3-(2,6-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]methyl ester (9CI) (CA INDEX NAME)



RN 474711-65-4 CAPLUS


CN 1H-Benzimidazole, 1-(4-fluorophenyl)-6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

$X = NR^4$, $R^4 = H$
 $R^1 = C$, alkyl.
 $W = iv$
 $R^2 = H$
 $R^3 = phenyl$


$R_1 = C$, alkyl
 subst. w/ph.

1052227a

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 474711-70-1 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 474711-73-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylthio)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 474711-77-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylthio)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 474711-78-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 474711-75-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 474711-76-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 474711-79-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 474711-82-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Karen Cheng

1052227a

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 474711-84-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 474712-65-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:607249 CAPLUS
DOCUMENT NUMBER: 125:247806
TITLE: Preparation of pyrazole derivatives as antiviral agents
INVENTOR(S): Kai, Yasunobu; Tsuruoka, Akihiko; Yanagisawa, Manabu; Takeuchi, Hitoshi; Taniguchi, Hiroyuki; Tanabe, Kazunori; Yamanaka, Motosuke
PATENT ASSIGNEE(S): Eisai Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 38 pp.
CODEN: JKKXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------|------|----------|-----------------|----------|
| JP 08183787 | A | 19960716 | JP 1994-328129 | 19941228 |
| JP 3734180 | B2 | 20060111 | JP 1994-328129 | 19941228 |

OTHER SOURCE(S): MARPAT 125:247806

GI For diagram(s), see printed CA Issue.


AB The title compds. I (ring A = (un)substituted aromatic ring (which may have one or more hetero atoms), etc.; R1 = alkyl, etc.; R2 = H, etc.; R3 = H, halo, etc.) are prepared. The title compound II (preparation given) in vitro showed

IC50 of <0.016 µg/mL against herpes simplex virus type 1.

IT 181865-74-7P 181865-75-8P 181865-76-9P
181865-77-0P 181865-82-7P 181865-84-9P
181865-86-1P 181865-90-7P 181865-94-1P
181866-01-3P 181866-04-6P 181866-07-9P
181866-22-8P 181866-30-8P 181866-39-7P
181866-49-9P 181866-56-8P 181866-70-6P
181866-72-8P 181866-74-0P 181866-78-4P
181866-79-5P 181866-80-8P 181867-98-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrazole derivs. as antiviral agents)

RN 181865-74-7 CAPLUS


CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 181865-75-8 CAPLUS

Karen Cheng

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 474712-66-8 CAPLUS
CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2,6-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN 1H-Benzimidazole, 5-[3-(4-fluorophenyl)-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 181865-76-9 CAPLUS
CN 1H-Benzimidazole, 5-[3-(4-fluorophenyl)-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 181865-77-0 CAPLUS
CN 1H-Benzimidazole, 1-ethyl-6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 181865-82-7 CAPLUS
CN 1H-Benzimidazole, 6-[3-(2,4-difluorophenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 181865-84-9 CAPLUS
CN 1H-Benzimidazole, 6-[3-(2-fluorophenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 181865-86-1 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 181865-90-7 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-[[2-(phenylmethoxy)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 181866-07-9 CAPLUS
CN 1H-Benzimidazole, 6-[3-(3,4-dimethoxyphenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 181866-22-8 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-[2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 181866-30-8 CAPLUS
CN 1H-Benzimidazole-1-ethanol, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)


Karen Cheng




RN 181865-94-1 CAPLUS
CN Ethanol, 2-[[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]methoxy]- (9CI) (CA INDEX NAME)




RN 181866-01-3 CAPLUS
CN 1H-Benzimidazole, 1-methyl-6-[3-(4-nitrophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 181866-04-6 CAPLUS
CN Benzenamine, 4-[4-(1-methyl-1H-benzimidazol-6-yl)-1H-pyrazol-3-yl]- (9CI)




RN 181866-39-7 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)




RN 181866-49-9 CAPLUS
CN 1H-Benzimidazole, 1-[2-(ethylthio)ethyl]-6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 181866-56-8 CAPLUS
CN 1H-Benzimidazole-1-acetic acid, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 181866-70-6 CAPLUS
CN 1H-Benzimidazole, 1-methyl-6-[3-(2-thienyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 181866-72-8 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-methoxyphenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 181866-74-0 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-bromophenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 181866-78-4 CAPLUS
CN 1H-Benzimidazole, 6-[3-(2-bromophenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 181866-79-5 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 181866-80-8 CAPLUS
CN Benzenamine, N,N-dimethyl-4-[4-(1-methyl-1H-benzimidazol-6-yl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 181867-98-1 CAPLUS
CN 1H-Benzimidazole, 1-methyl-6-[3-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)




IT 181865-90-5P 181866-94-4P 181866-95-5P
R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or Reagent)
(preparation of pyrazole derivs. as antiviral agents)

RN 181865-90-5 CAPLUS
CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-methyl- (9CI) (CA INDEX NAME)





RN 181866-94-4 CAPLUS
Karen Cheng

CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazol-4-yl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 181866-95-5 CAPLUS
CN 1H-Benzimidazole, 6-[5-(4-fluorophenyl)-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazol-4-yl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)





w/ w defined.
R5
X



chain nodes :

49 66 67 69 75 81

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 50 51 52 53
54 55 56 57 58 59 60 61 62 63 70 71 72 76 77 78 79

chain bonds :

21-49 50-69 51-81 52-66 53-67 71-75

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-10 7-8 8-9 9-10 11-12 11-15 12-13 13-14
14-15 16-17 16-20 17-18 18-19 19-20 21-22 21-25 22-23 23-24 24-25 26-27
26-30 27-28 28-29 29-30 31-32 31-35 32-33 33-34 34-35 36-37 36-40 37-38
38-39 39-40 50-51 50-55 51-52 52-53 53-54 54-55 54-70 55-72 56-60 56-57
56-76 57-58 57-79 58-59 58-61 59-60 59-63 61-62 62-63 70-71 71-72 76-77
77-78 78-79

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-10 7-8 8-9 9-10 11-12 11-15 12-13 13-14
14-15 16-17 16-20 17-18 18-19 19-20 21-22 21-25 21-49 22-23 23-24 24-25
26-27 26-30 27-28 28-29 29-30 31-32 31-35 32-33 33-34 34-35 36-37 36-40
37-38 38-39 39-40 50-69 51-81 52-66 53-67 54-70 55-72 56-60 56-57 56-76
57-58 57-79 58-59 58-61 59-60 59-63 61-62 62-63 70-71 71-72 71-75 76-77
77-78 78-79

normalized bonds :

50-51 50-55 51-52 52-53 53-54 54-55

isolated ring systems :

containing 50 :


G1:H,CH3

G2:S,N

G3:X,H,CH3,N

Karen Cheng


10522227duprem



=>

Uploading C:\Program Files\Stnexp\Queries\10522227c.str

w/ R⁵
X
W and R³
defined but w/
diff.
point
of attach
for
R³=thienyl



attach here

chain nodes :

49 66 67 69 75 81 96 97 98 100 101 102 103 104 105

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 50 51 52 53
54 55 56 57 58 59 60 61 62 63 70 71 72 76 77 78 79 83 84 85 86
87 88 89 90 91 92 93

chain bonds :

5-96 10-97 12-98 16-100 21-49 25-101 29-102 32-103 39-104 50-69 51-81
52-66 53-67 62-105 71-75

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-10 7-8 8-9 9-10 11-12 11-15 12-13 13-14
14-15 16-17 16-20 17-18 18-19 19-20 21-22 21-25 22-23 23-24 24-25 26-27
26-30 27-28 28-29 29-30 31-32 31-35 32-33 33-34 34-35 36-37 36-40 37-38
38-39 39-40 50-51 50-55 51-52 52-53 53-54 54-55 54-70 55-72 56-60 56-57
56-76 57-58 57-79 58-59 58-61 59-60 59-63 61-62 62-63 70-71 71-72 76-77
77-78 78-79 83-84 83-87 84-85 85-86 86-87 88-89 88-93 89-90 90-91 91-92
92-93

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 5-96 6-7 6-10 7-8 8-9 9-10 10-97 11-12 11-15
12-13 12-98 13-14 14-15 16-17 16-20 16-100 17-18 18-19 19-20 21-22 21-25
21-49 22-23 23-24 24-25 25-101 26-27 26-30 27-28 28-29 29-30 29-102
31-32 31-35 32-33 32-103 33-34 34-35 36-37 36-40 37-38 38-39 39-40
39-104 50-69 51-81 52-66 53-67 54-70 55-72 56-60 56-57 56-76 57-58 57-79
Kaleh Cheng 58-59 58-61 59-60 59-63 61-62 62-63 62-105 70-71 71-72 71-75 76-77
77-78 78-79 83-84 83-87 84-85 85-86 86-87

10522227duprem

normalized bonds :

50-51 50-55 51-52 52-53 53-54 54-55 88-89 88-93 89-90 90-91 91-92 92-93

isolated ring systems :

containing 50 :

G1:H,CH3

G2:S,N

G3:X,H,CH3,N

G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9]

G5:[*10],[*11]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 49:CLASS 50:Atom 51:Atom 52:Atom 53:Atom 54:Atom
55:Atom 56:Atom 57:Atom 58:Atom 59:Atom 60:Atom 61:Atom 62:Atom 63:Atom
66:CLASS 67:CLASS 69:CLASS 70:CLASS 71:CLASS 72:CLASS 75:CLASS 76:Atom
77:Atom 78:Atom 79:Atom 81:CLASS 83:Atom 84:Atom 85:Atom 86:Atom 87:Atom
88:Atom 89:Atom 90:Atom 91:Atom 92:Atom 93:Atom 96:CLASS 97:CLASS 98:CLASS
100:CLASS 101:CLASS 102:CLASS 103:CLASS 104:CLASS 105:CLASS

L8 STRUCTURE UPLOADED

=> d

L8 HAS NO ANSWERS

L8 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 18:21:08 ON 08 FEB 2007)

FILE 'REGISTRY' ENTERED AT 18:21:37 ON 08 FEB 2007

L1 STRUCTURE UPLOADED

L2 43 S L1

L3 898 S L1 FULL

FILE 'CAPLUS' ENTERED AT 18:22:06 ON 08 FEB 2007

L4 43 S L3

FILE 'STNGUIDE' ENTERED AT 18:22:24 ON 08 FEB 2007

FILE 'REGISTRY' ENTERED AT 18:32:38 ON 08 FEB 2007

L5 STRUCTURE UPLOADED

Karen Cheng

10522227duprem

=> d his

(FILE 'HOME' ENTERED AT 18:21:08 ON 08 FEB 2007)

FILE 'REGISTRY' ENTERED AT 18:21:37 ON 08 FEB 2007

L1 STRUCTURE UPLOADED

L2 43 S L1

L3 898 S L1 FULL

FILE 'CAPLUS' ENTERED AT 18:22:06 ON 08 FEB 2007

L4 43 S L3

FILE 'STNGUIDE' ENTERED AT 18:22:24 ON 08 FEB 2007

FILE 'REGISTRY' ENTERED AT 18:32:38 ON 08 FEB 2007

L5 STRUCTURE UPLOADED

L6 596 S L5 FULL SUB=L3

FILE 'CAPLUS' ENTERED AT 18:33:19 ON 08 FEB 2007

L7 7 S L6

FILE 'REGISTRY' ENTERED AT 18:37:43 ON 08 FEB 2007

L8 STRUCTURE UPLOADED

L9 596 S L8 FULL SUB=L3

L10 1192 DUP REM L6 L9 (0 DUPLICATES REMOVED)

FILE 'CAPLUS' ENTERED AT 18:40:22 ON 08 FEB 2007

L11 7 S L9

L12 7 DUP REM L7 L11 (7 DUPLICATES REMOVED)

=> d ibib abs l12 tot

prior search
current search
of structure
results
current search

no duplicates